Keskin Serkan, Kutluk Ali Cevat, Tas Faruk
Department of Medical Oncology, Memorial Hospital, Istanbul, Turkey. Email:
Department of Thoracic Surgery, Yedikule Education and Research Hospital, Istanbul, Turkey.
Asian Pac J Cancer Prev. 2019 Mar 26;20(3):733-736. doi: 10.31557/APJCP.2019.20.3.733.
Objective: Despite the existence of detailed consensus guidelines, challenges remain regarding the role angiogenetic factors on non-small cell lung cancer (NSCLC). This study was conducted to determine the role of the vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin2 (Ang2) in patients with NSCLC. Methods: This study included 64 consecutive patients with non-small cell lung cancer, who admitted to clinic. Pre-treatment serum VEGF, IL-8 and Ang2 levels were evaluated. Patients were treated according to internationally accepted guidelines. Results: VEGF and IL-8 serum levels of patients with both squamous cell carcinoma and adenocarcinoma were significantly higher than controls (p<0.05). In addition, IL-8 levels were lower among treatment-responders than non-responders (p:0.031). Impact of elevated or decreased levels of VEGF, Ang2 and IL-8 on survival was evaluated, accepting median level as reference. There was no correlation between the serum levels of VEGF, Ang2, IL-8 and survival. Conclusion: We found that the levels of angiogenic markers were significantly different between non-small cell lung cancer patients and controls. These markers could elicit more information related to stage and prognosis.
尽管存在详细的共识指南,但血管生成因子在非小细胞肺癌(NSCLC)中的作用仍存在挑战。本研究旨在确定血管内皮生长因子(VEGF)、白细胞介素-8(IL-8)和血管生成素2(Ang2)在NSCLC患者中的作用。方法:本研究纳入了64例连续入院的非小细胞肺癌患者。评估治疗前血清VEGF、IL-8和Ang2水平。患者按照国际公认的指南进行治疗。结果:鳞状细胞癌和腺癌患者的VEGF和IL-8血清水平均显著高于对照组(p<0.05)。此外,治疗反应者的IL-8水平低于无反应者(p:0.031)。以中位数水平为参考,评估VEGF、Ang2和IL-8水平升高或降低对生存的影响。VEGF、Ang2、IL-8的血清水平与生存之间无相关性。结论:我们发现非小细胞肺癌患者与对照组之间血管生成标志物水平存在显著差异。这些标志物可以提供更多与分期和预后相关的信息。